Immunovant (IMVT) Competitors $23.86 +0.06 (+0.25%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMVT vs. SMMT, MRNA, RDY, CTLT, SRPT, QGEN, PCVX, ASND, ROIV, and RVMDShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Immunovant vs. Summit Therapeutics Moderna Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Qiagen Vaxcyte Ascendis Pharma A/S Roivant Sciences Revolution Medicines Immunovant (NASDAQ:IMVT) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk. Which has preferable earnings and valuation, IMVT or SMMT? Immunovant has higher earnings, but lower revenue than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$259.34M-$2.22-10.75Summit Therapeutics$700K20,048.11-$614.93M-$0.28-67.96 Do institutionals & insiders believe in IMVT or SMMT? 47.1% of Immunovant shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.9% of Immunovant shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer IMVT or SMMT? In the previous week, Immunovant had 24 more articles in the media than Summit Therapeutics. MarketBeat recorded 30 mentions for Immunovant and 6 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.71 beat Immunovant's score of 0.22 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 8 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, IMVT or SMMT? Immunovant has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.87, meaning that its share price is 187% less volatile than the S&P 500. Is IMVT or SMMT more profitable? Immunovant's return on equity of -56.40% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -56.40% -52.03% Summit Therapeutics N/A -85.42%-52.66% Does the MarketBeat Community believe in IMVT or SMMT? Summit Therapeutics received 178 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.99% of users gave Immunovant an outperform vote while only 58.30% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformImmunovantOutperform Votes12477.99% Underperform Votes3522.01% Summit TherapeuticsOutperform Votes30258.30% Underperform Votes21641.70% Do analysts prefer IMVT or SMMT? Immunovant presently has a consensus price target of $47.00, indicating a potential upside of 96.98%. Summit Therapeutics has a consensus price target of $33.57, indicating a potential upside of 76.41%. Given Immunovant's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immunovant is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryImmunovant beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49B$2.96B$5.35B$9.07BDividend YieldN/A1.94%5.13%4.02%P/E Ratio-10.7545.5689.4817.34Price / SalesN/A358.911,252.31134.70Price / CashN/A192.9043.7535.97Price / Book5.613.975.324.80Net Income-$259.34M-$41.02M$122.60M$224.91M7 Day Performance1.62%8.62%0.88%1.90%1 Month Performance-9.10%10.70%4.81%5.08%1 Year Performance-41.14%5.54%27.90%21.15% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant1.9921 of 5 stars$23.86+0.3%$47.00+97.0%-41.7%$3.49BN/A-10.75120Analyst ForecastInsider TradeNews CoverageSMMTSummit Therapeutics2.8416 of 5 stars$18.02+1.0%$33.57+86.3%+468.1%$13.29B$700,000.00-64.35105MRNAModerna4.7326 of 5 stars$34.19-19.1%$78.83+130.6%-66.1%$13.16B$5.06B-5.875,600Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHigh Trading VolumeRDYDr. Reddy's Laboratories2.0121 of 5 stars$15.28-0.9%$17.00+11.3%+10.6%$12.75B$3.35B24.4127,048News CoverageCTLTCatalent1.2507 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900News CoverageSRPTSarepta Therapeutics4.9256 of 5 stars$117.14-6.1%$178.71+52.6%+0.8%$11.19B$1.64B93.711,314Analyst ForecastAnalyst RevisionNews CoverageQGENQiagen4.0945 of 5 stars$45.97+2.9%$51.50+12.0%-0.2%$10.49B$1.97B117.875,967Short Interest ↓News CoveragePCVXVaxcyte1.9841 of 5 stars$80.53-0.7%$145.71+80.9%+35.7%$10.04BN/A-17.51160Insider TradeAnalyst RevisionNews CoverageASNDAscendis Pharma A/S3.6129 of 5 stars$131.74+2.0%$192.07+45.8%-3.2%$8.00B$327.43M-16.30640Short Interest ↓ROIVRoivant Sciences3.6806 of 5 stars$10.68+0.5%$17.93+67.9%+3.6%$7.77B$129.13M1.89860Insider TradeOptions VolumePositive NewsRVMDRevolution Medicines4.4701 of 5 stars$42.22+1.1%$66.25+56.9%+50.2%$7.10B$742,000.00-11.76250News Coverage Related Companies and Tools Related Companies SMMT Competitors MRNA Competitors RDY Competitors CTLT Competitors SRPT Competitors QGEN Competitors PCVX Competitors ASND Competitors ROIV Competitors RVMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMVT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
